Liquidia LQDA 深 沪
等待开盘 10-06 09:30:00 美东时间
27.64
-1.000
-3.49%
华盛通- 最 高74.74
- 今 开28.21
- 成交量 768.28万股
- 最 低 22.31
- 昨 收 28.64
- 总市值 177.85万
- 52周最高 93.61
- 市盈率 静 --
- 换手率 11940.04%
- 52周最低 21.94
- 委 比 -99.90%
- 总股本 6.43万
- 历史最高 93.61
- 量 比 0.69
- 振 幅 183.07%
- 历史最低 1.10
- 每 手 1
- 风险率 20.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Apple To $355? Here Are 10 Top Analyst Forecasts For Thursday
Analysts raised targets for HPE, Phillips 66, Micron and AEON; cut targets for Liquidia, Apple and Zions.
10-02 02:10
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia
Shares of United Therapeutics are rising Thursday following a federal court victory in its patent litigation against competitor Liquidia.
10-01 20:14
BTIG Downgrades Liquidia to Neutral
BTIG analyst Julian Harrison downgrades Liquidia (NASDAQ:LQDA) from Buy to Neutral.
10-01 18:01
Why is Liquidia (LQDA) Stock Trending After Hours?
Liquidia Corp. shares gained 0.13% after hours after closing 57.19% lower following an adverse patent ruling.
10-01 11:29
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
Earnings Scheduled For March 5, 2026
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
Analyst Expectations For Liquidia's Future
Liquidia (NASDAQ:LQDA) underwent analysis by 5 analysts in the last quarter, re...
01-13 20:00
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
2025-11-03 19:11
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
Liquidia's YUTREPIA, a treprostinil inhalation powder for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), is now available via specialty pharmacies following FDA approval on May 23, 2025. The commercial launch was achieved in just five business days and court denied a preliminary injunction against it. YUTREPIA aims to provide a new treatment option for patients with these conditions.
2025-06-02 10:30
